Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Eli Lilly Smashes Forecasts As Mounjaro Sales Rocket 652%

Eli Lilly stock rose early Thursday after diabetes blockbuster Mounjaro helped the company beat sales expectations.

Investors Business Daily

Eli Lilly slashes 2023 profit outlook despite weight-loss drug earnings boost

Eli Lilly's Mounjaro, a diabetes drug that is expected to received FDA approval for weight loss treatment, generated more than $1.4 billion in September quarter revenues.

The Street

Verve Stock Soars On $250 Million Eli Lilly Deal

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The Point At Which IBD Stock Of The Day Eli Lilly Could Become Actionable Again

Eli Lilly is Friday's IBD Stock Of The Day. After announcing an acquisition, Eli Lilly stock is bounding off its 50-day moving average.

Investors Business Daily

Why Eli Lilly's $1.4 Billion Takeover Is A Boon For More Than Just Point Biopharma

Eli Lilly said Tuesday it will buy cancer specialist Point Biopharma Global for $1.4 billion, launching PNT stock to a two-year high.

Investors Business Daily

Point Biopharma stock soars on $1.4B takeover bid from Eli Lilly

Eli Lilly will add to its growing oncology business with the $1.4 billion takeover of Point Biopharma Global

The Street

These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs

After a run, stocks can offer a new buying opportunity with a pullback to the 50-day line. Novo Nordisk and 4 S&P 500 stocks have done that.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Prescribe to Profits With These 3 Pharma Stocks

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

StockNews.com

3 Pharma Stocks Smart Money Is Following in September

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

StockNews.com

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

Barchart

How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment

Novo Nordisk said Friday its obesity treatment, Wegovy, reduced heart-failure symptoms. But Novo Nordisk stock remained flat.

Investors Business Daily

Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo

Prescriptions of weight-loss and diabetes drugs have rocketed this year, giving Novo Nordisk stock and Eli Lilly stock more room to run.

Investors Business Daily

Is Eli Lilly Stock A Sell After Its Disastrous Third-Quarter Report?

Is Eli Lilly stock a sell after third-quarter sales of its diabetes and obesity drugs missed forecasts? Is LLY stock a sell?

Investors Business Daily

Why The Weight-Loss Bonanza Catapulted Lilly And Novo, But Hammered Dexcom And Others

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

Investors Business Daily

Eli Lilly Surges 15% After Diabetes Powerhouse Mounjaro Fuels Beat And Raise

Eli Lilly stock broke out bullishly Tuesday after the drugmaker walloped forecasts partly due to diabetes treatment powerhouse Mounjaro.

Investors Business Daily

AI Stock Marvell And Eli Lilly Lead 5 Names Near Buy Points As S&P 500 Rallies On

Top AI stock Marvell Technology and Eli Lilly lead this weekend's watch list of five stocks near buy points as the new S&P 500 bull market revs back up.

Investors Business Daily

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Microsoft, Eli Lilly Bolster Stock Market Upside; This Sector Is Smashing The Dow Jones Industrial Average's Performance

ARCB also is trying to storm past a cup with handle that shows a 101.49 buy point.

Investors Business Daily

IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout

Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears "very competitive" with Biogen's.

StockNews.com

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

Tribune News Service

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

The Independent UK

Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening

Investors Business Daily

How Weight-Loss Behemoth Lilly Is Trying To Leapfrog Chief Rival Novo

Eli Lilly stock jumped Friday after unveiling a nearly $2 billion takeover that could bolster its efforts among weight-loss drugs.

Investors Business Daily

S&P 500, Nasdaq Hit Fresh 52-Week Highs As Inflation Fears Ebb; Salesforce, Delta, JPMorgan In Focus: Weekly Review

The S&P 500 and Nasdaq led a strong market rally this week as inflation fears wane. Salesforce, Delta Air Lines, JPMorgan were key newsmakers

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.